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Prior studies showed conflicting results regarding the
association between 25-hydroxyvitamin D (25(OH)D) levels
and mineral metabolism in end-stage renal disease. In order
to determine whether the bioavailable vitamin D (that
fraction not bound to vitamin D–binding protein) associates
more strongly with measures of mineral metabolism than
total levels, we identified 94 patients with previously
measured 25(OH)D and 1,25-dihydroxyvitamin D
(1,25(OH)2D) from a cohort of incident hemodialysis patients.
Vitamin D–binding protein was measured from stored serum
samples. Bioavailable 25(OH)D and 1,25(OH)2D were
determined using previously validated formulae. Associations
with demographic factors and measures of mineral
metabolism were examined. When compared with whites,
black patients had lower levels of total, but not bioavailable,
25(OH)D. Bioavailable, but not total, 25(OH)D and 1,25(OH)2D
were each significantly correlated with serum calcium. In
univariate and multivariate regression analysis, only
bioavailable 25(OH)D was significantly associated with
parathyroid hormone levels. Hence, bioavailable vitamin D
levels are better correlated with measures of mineral
metabolism than total levels in patients on hemodialysis.
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Chronic kidney disease (CKD)–associated mineral and bone
disorder is one of the most appreciated metabolic complica-
tions of CKD. As individuals progress toward end-stage renal
disease (ESRD), declining renal 1a-hydroxylase activity leads
to decreased conversion of 25-hydroxyvitamin D (25(OH)D)
to the active 1,25-dihydroxyvitamin D (1,25(OH)2D). These
metabolic changes are believed to precipitate the hypo-
calcemia and secondary hyperparathyroidism that character-
ize CKD–associated mineral and bone disorder. Although
1,25(OH)2D is thought to be the biologically active moiety,
the majority of vitamin D circulates as 25(OH)D.1 Low levels
of 25(OH)D are common in ESRD; 79% of patients initiating
dialysis have 25(OH)D levels below 30 ng/ml, and serum
levels below this threshold are nearly universal among black
ESRD patients.2
The free hormone hypothesis suggests that protein-bound
hormones are relatively inactive, whereas those liberated
from binding proteins are free to exert biological activity.3
For some hormones (e.g., testosterone), binding to albumin
is considerably weaker than to a specific binding protein.
Thus, albumin-bound hormone is often grouped with the
free fraction and referred to as the ‘bioavailable’ fraction. The
majority (85–90%) of circulating 25(OH)D and 1,25(OH)2D
is tightly bound to vitamin D–binding protein (DBP), with
a smaller amount (10–15%) loosely bound to albumin. Less
than 1% of circulating vitamin D exists in a free, unbound
form.4,5 We previously demonstrated that bioavailable
25(OH)D is more tightly associated with bone density than
total levels in healthy individuals.6
We hypothesized that the relationship between vitamin D
and markers of mineral metabolism (e.g., parathyroid
hormone (PTH) and calcium) in ESRD would be strength-
ened by the use of DBP and albumin to determine
bioavailable vitamin D levels. Given the patterns observed
in other cohorts, we further hypothesized that the lower total
25(OH)D levels typically seen in black dialysis patients would
not necessary be associated with lower bioavailable vitamin D
levels in this group.6,7
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RESULTS
Baseline characteristics of the 94 subjects included in this
analysis, which are similar to those of a typical US hemo-
dialysis population, are summarized in Table 1. None of the
included subjects were recorded as receiving treatment with
activated vitamin D, ergocalciferol, or cholecalciferol before
initiating dialysis.
Mineral metabolism and vitamin D
Baseline-corrected calcium levels, measured within 14 days of
chronic hemodialysis initiation, were not associated with total
levels of either 25(OH)D (r¼ 0.01, P¼ 0.92) or 1,25(OH)2D
(r¼ 0.08, P¼ 0.44). In contrast, calcium levels correlated
positively with both bioavailable 25(OH)D (r¼ 0.26, P¼ 0.01)
and bioavailable 1,25(OH)2D (r¼ 0.23, P¼ 0.02). The rela-
tionships of total and bioavailable 25(OH) vitamin D with
calcium are shown in Figure 1. A single individual with the
highest bioavailable 25(OH)D and bioavailable 1,25(OH)2D
appeared to be an outlier with respect to the observed
relationships, with both levels over four standard deviations
above the mean. To examine the impact of this single data
point, we performed a sensitivity analysis by repeating the
analysis with this individual excluded. The relationship of
calcium with bioavailable 25(OH)D (r¼ 0.30, P¼ 0.003) and
bioavailable 1,25(OH)2D (r¼ 0.27, P¼ 0.008) were both
somewhat strengthened.
Phosphorus levels demonstrated no association with either
total levels of 25(OH)D (r¼ 0.14, P¼ 0.19) or 1,25(OH)2D
(r¼0.01, P¼ 0.94). Similarly, neither bioavailable 25(OH)D
(r¼0.10. P¼ 0.32) nor bioavailable 1,25(OH)2D (r¼0.16,
P¼ 0.12) were significantly associated with phosphorus levels.
Alkaline phosphatase was not associated with either total
or bioavailable forms of 25(OH)D or 1,25(OH)2D (P40.05
for all comparisons).
The relationship between PTH and all four forms of
vitamin D were examined in univariate and multivariate
regression models. In univariate models, only bioavailable
25(OH)D was associated with PTH, with a 0.35 log decrease
in PTH for each log increase in bioavailable 25(OH)D
(P¼ 0.01). In a multivariate model controlling for age, gender,
race, and survival status at 1 year, this relationship remained
unchanged (b¼0.32, P¼ 0.02). A third model adding
calcium, phosphorus, and bioavailable 1,25(OH)2D levels
demonstrated similar results (Table 2). As with the calcium
findings, both the unadjusted and adjusted coefficients became
stronger when a single outlier was excluded (unadjusted:
b¼0.40, P¼ 0.003; adjusted: b¼0.36, P¼ 0.01). In
contrast, there was no significant association between total
25(OH)D and PTH (Figure 2).
Patient factors and vitamin D
Older individuals had higher total 25(OH)D levels (r¼ 0.31,
P¼ 0.003) and bioavailable 25(OH)D (r¼ 0.21, P¼ 0.04).
Neither total nor bioavailable 1,25(OH)2D were associated with
age. Female gender was associated with lower total 25(OH)D
levels (median in men: 22.0 ng/dl, in women: 18.0 ng/dl;
P¼ 0.03). Although women had numerically lower median
total 1,25(OH)2D and bioavailable 25(OH)D and 1,25(OH)2D
levels, none of these differences were statistically significant.
Black individuals had lower total 25(OH)D levels
(median: 15.2 vs. 23.2 ng/ml, Po0.001), but not bioavailable
25(OH)D levels (median: 3.8 vs. 2.8 ng/ml, P¼ 0.21). The
Table 1 | Characteristics of the population (n=94)
Median (IQR) or n (%)
Age (years) 65 (50–74)
Male 55 (59%)
Black race 48 (51%)
Survived at least 1 year on dialysis 47 (50%)
Body mass index 25 (22–30)
Systolic blood pressure (mmHg) 140 (123–153)
Diastolic blood pressure (mmHg) 73 (61–81)
Total 25(OH)D (ng/ml) 20 (13–28)
Total 1,25(OH)2D (pg/ml) 9.5 (5–16)
Parathyroid hormone (pg/ml) 190 (96–307)
Corrected calcium (mg/dl) 8.9 (8.5–9.4)
Phosphorus (mg/dl) 4.2 (3–5.5)
Alkaline phosphatase (mg/dl) 82 (66–112.5)
Albumin (g/dl) 3.4 (3.0–3.8)
Vitamin D–binding protein (mg/ml) 158 (69–217)
Bioavailable 25(OH)D (ng/ml) 3.4 (2.2–5.0)
Bioavailable 1,25(OH)2D (pg/ml) 2.2 (1.1–3.8)
Abbreviations: 1,25(OH)2D, 1,25-dihydroxyvitamin D; 25(OH)D, 25-hydroxyvitamin D;
IQR, interquartile range.
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Figure 1 |Total vs. bioavailable 25-hydroxyvitamin D
(25(OH)D) and serum calcium. Total levels of 25(OH)D (left
panel) demonstrated no association with serum calcium levels
(corrected for albumin), whereas bioavailable 25(OH)D levels
(right panel) were positively associated with serum calcium.
Table 2 | PTH and bioavailable 25(OH) vitamin D
b P
Bioavailable 25(OH)D alone 0.36 0.007
Multivariate model adding age, gender, race 0.33 0.02
Multivariate model with above variables plus
survival status at 1 year
0.32 0.02
Multivariate model with above variables plus
calcium, phosphorus, bioavailable 1,25(OH)2D
0.39 0.02
Abbreviations: 1,25(OH)2D, 1,25-dihydroxyvitamin D; 25(OH)D, 25-hydroxyvitamin D;
PTH, parathyroid hormone.
In univariate and multivariate analyses, bioavailable 25(OH) vitamin D levels were
consistently associated with PTH (corresponding P values displayed). PTH and
bioavailable vitamin D levels were log transformed before analysis, thus b=0.36
suggests that a 25% increase in bioavailable 25(OH)D is associated with 7.7%
decrease in PTH ((1.250.361) 100=7.7).
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contrast in racial differences between these two forms of
vitamin D was driven largely by lower DBP levels among
blacks. This difference persisted even when examining only
individuals who survived for 1 year on dialysis or those who
died in this time frame (Table 3). PTH levels did not differ
significantly by race (median: 201 pg/ml (black) vs. 168 pg/ml
(white), P¼ 0.47). Neither total nor bioavailable 1,25(OH)2D
levels differed by race (P¼ 0.07 and 0.49, respectively). It is
noteworthy that we found no racial differences in systolic or
diastolic blood pressure, diabetes, or body mass index.
Systolic and diastolic blood pressure, body mass index,
and survival were not associated with any form of vitamin D.
Similarly, there was no association between any form of
vitamin D and either a diagnosis of diabetic nephropathy or
diabetes (data not shown). The study was not specifically
powered to address these factors.
Sensitivity analysis
Sensitivity analyses were performed to address the possibility
that uremia might alter DBP’s binding affinity with 25(OH)D
or 1,25(OH)2D. With DBP-binding coefficients that were
25% lower than those originally determined by Bikle et al.,4,5
bioavailable measures of both 25(OH)D (r¼ 0.26, P¼ 0.01)
and 1,25(OH)2D (r¼ 0.22, P¼ 0.03) remained associated
with corrected calcium. Similar results were observed with
25% higher coefficients (bioavailable 25(OH)D: r¼ 0.27,
P¼ 0.009; bioavailable 1,25(OH)2D: r¼ 0.24, P¼ 0.02).
Associations of bioavailable 25(OH)D with PTH remained
statistically significant in both cases, with association
coefficients changing o12% in either univariate or multi-
variate analyses.
DISCUSSION
Using a retrospective cohort of incident dialysis patients, we
studied the relationship between measures of mineral
metabolism (including serum calcium and PTH) with both
total and bioavailable levels of vitamin D. In a prior study, we
had assessed the possibility that the free hormone hypothesis
could explain discrepant findings in the relationship between
bone mineral density and 25(OH)D levels in healthy young
individuals without CKD. We found that bioavailable
25(OH)D levels were predictive of bone density (as measured
by dual X-ray absorptiometry), whereas total 25(OH)D levels
were not.6 We further found that bioavailable levels, which
combine free and albumin-bound hormone, were more
strongly associated with bone mineral density than free
hormone levels alone. In the present study, we similarly found
that bioavailable 25(OH)D was associated with both corrected
serum calcium levels and PTH, both of which are well-
established measures of mineral metabolism in ESRD, whereas
total 25(OH)D demonstrated no such associations. These data
build upon our prior findings: analysis from two separate
cohorts now supports the hypothesis that bioavailable
measures of vitamin D, which take into account binding of
vitamin D to albumin and DBP, are more strongly linked to
biological outcomes than are total levels, which are currently
the standard measure of vitamin D status.
Some in vitro studies suggest that DBP-binding limits
vitamin D activity in multiple target cells.8,9 Studies of DBP-
null mice have shown that these animals display markedly
reduced levels of 25(OH)D and 1,25(OH)2D compared with
wild-type mice, with a reduced half-life.10 Despite their low
vitamin concentrations, when these mice are provided with a
steady source of dietary vitamin D they show no differences
in serum calcium, phosphorus, alkaline phosphatase, and
PTH compared with wild-type controls. These studies
support the application of the free hormone hypothesis to
vitamin D physiology, at least for some biological actions.
Despite these findings, uptake of protein-bound hormone in
cells expressing megalin appears to be important for some
processes, and thus the biology underlying our findings may
be more complex than is immediately apparent and warrants
further investigation.11,12
We oversampled black patients, as our prior data from a
separate cohort suggested that blacks have lower DBP levels
than whites, an observation supported by this study. As
previously reported, we and others observed that black race is
associated with lower levels of total 25(OH)D.2,13 As might
be expected from these two parallel racial differences
(lower total 25(OH)D and lower DBP in blacks vs. whites),
we found that levels of bioavailable 25(OH)D are similar
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Figure 2 | Total vs. bioavailable 25-hydroxyvitamin D
(25(OH)D) and parathyroid hormone (PTH). After adjustment
for age, gender, race, and survival status at 1 year, bioavailable
25(OH)D was significantly negatively associated with PTH levels,
whereas total 25(OH)D demonstrated no association with PTH.
Table 3 | Race and vitamin D levels
Blacks Whites P
Total 25(OH)D (ng/ml) 15.1 23.1 o0.001
Bioavailable 25(OH)D (ng/ml) 3.8 2.8 0.21
Total 1,25(OH)2D (pg/ml) 8 11.5 0.07
Bioavailable 1,25(OH)2D (pg/ml) 2.2 2.2 0.48
DBP (mg/ml) 75 189 o0.001
Survivors: DBP (mg/ml) 88 195 0.004
Non-survivors: DBP (mg/ml) 58 183 o0.001
PTH (pg/ml) 201 168 0.47
Abbreviations: 1,25(OH)2D, 1,25-dihydroxyvitamin D; 25(OH)D, 25-hydroxyvitamin D;
DBP, vitamin D–binding protein; PTH, parathyroid hormone.
Black individuals had lower total, but not bioavailable, 25(OH)D levels when
compared with their white counterparts. Survivors are patients who survived for at
least 1 year after initiating hemodialysis, while non-survivors died within this year.
All values represent group medians.
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between the races. Black individuals are thought to have
decreased cutaneous synthesis of vitamin D because the
higher concentrations of melanin limit available ultraviolet
energy exposure in the skin. Lower DBP levels may be an
adaptive response in black individuals to reduce the risk of
functional vitamin D deficiency in the setting of decreased
production of 25(OH)D. These racial relationships will need
to be confirmed in the general population.
Despite similar bioavailable D levels between racial
groups, and association between bioavailable 25(OH)D and
PTH, black patients had numerically higher PTH levels than
their white counterparts. Although this difference was not
statistically significant in our sample, larger samples from this
cohort have found significantly higher levels of PTH in black
individuals.14 Bioavailable 25(OH)D did not differ by race,
yet were negatively associated with PTH, suggesting that
racial differences in PTH are not primarily driven by
differences in 25(OH)D. Indeed, others have found that
PTH levels in blacks are higher than those in whites, even in
states of 25(OH)D sufficiency.13
Several studies have attempted to assess the metabolic
consequences of low 25(OH)D levels in advanced CKD and
ESRD, but have yielded conflicting results. Ergocalciferol, a
form of nutritional vitamin D that can increase 25(OH)D
levels, appears to affect PTH levels in stage 3, but not in stage
4, CKD.15,16 Moreover, some studies have demonstrated a
significant association between 25(OH)D levels and PTH in
ESRD,17–19 whereas others have not.20,21 Associations between
25(OH)D and serum calcium have been similarly mixed.2,17,22
These contradictory data have led to confusion about the
role that repleting 25(OH)D (e.g., with nutritional forms of
vitamin D such as cholecalciferol or ergocalciferol) has in
the management of patients with ERSD.23,24 To study the role
of vitamin D deficiency and identify patients who are most
likely to benefit from repletion, it is critical to have a
biologically relevant measure of vitamin D status. Notably,
our study failed to find any significant link between total or
bioavailable 1,25(OH)2D and relevant measures of mineral
metabolism, echoing the general consensus that circulating
serum levels of the active hormone are not useful as a
measure of vitamin D status.1
We did not find a relationship between survival and
vitamin D status, although this sample had considerably less
power to detect this relationship than prior studies, which
have found that severe vitamin D deficiency (typically defined
as levels o10 ng/ml) is associated with increased mortal-
ity.19,25,26 Larger studies will be needed to identify differences
in mortality associations between total and bioavailable levels
of vitamin D.
This study used a relatively small sample of dialysis patients,
and thus it will be important to study these relationships in
additional cohorts. None of the individuals in this analysis,
who initiated dialysis in 2004 or 2005, had been treated with
activated vitamin D analogs before initiating dialysis. Although
this simplified our analysis, the use of these agents in pre-
dialysis CKD is increasingly common. It will therefore be
important to determine the effects of these analogs on DBP
and bioavailable vitamin D levels and on the relationship
between bioavailable vitamin D levels and clinically relevant
outcomes. PTH is commonly used as a proxy for metabolic
bone disease in dialysis patients, but has an imperfect associa-
tion with bone disease.27 Bone biopsies and noninvasive mea-
sures of bone density and structure were not available in this
study and are potential targets for future analyses. Although
we previously demonstrated a relationship between bioavail-
able 25(OH)D and bone density in a healthy population,6 it is
not certain that this relationship will extend to the ESRD
population given known alterations in mineral metabolism.
Metabolic changes that accompany ESRD and/or dialysis,
as well as genetic variants in DBP or other relevant proteins,
have the potential to influence binding of 25(OH)D to DBP.
Whereas our sensitivity analysis did not indicate that these
factors are likely to affect the fundamental findings of this
study, studies that directly measure bound and unbound
fractions could improve upon our initial estimates and the
equations used. Finally, it is possible that measured 25(OH)D
levels in this study were influenced by levels of 24,25(OH)D.
Confirmation of our findings with assays able to differentiate
25(OH)D, 24,25(OH)D, and 1,24,25(OH)D may further
elucidate these biological relationships.
This study provides additional evidence to support the
notion that bioavailable, rather than total, levels of vitamin D
may be more relevant measures of vitamin D status with
respect to its actions on mineral metabolism. Although mineral
metabolism has been the traditional focus of vitamin D actions,
recent data suggest that its actions may be more widespread,
with effects on the immune response,28 hypertension,29 and
insulin sensitivity,30 among others. Studies assessing the effects
of albumin and DBP in modifying these relationships will shed
further light on the best way to identify individuals who are
most likely to benefit from supplementation.
MATERIALS AND METHODS
Accelerated Mortality on Renal Replacement (ArMORR) is a
nationally representative prospective cohort study of incident
chronic hemodialysis patients (n¼ 10,044) who began renal
replacement between 1 July 2004 and 30 July 2005 at one of the
1056 dialysis centers in the US operated by Fresenius Medical Care,
North America (FMC).31 The ArMORR data set contains a broad
range of demographic and clinical data including coexisting medical
conditions, laboratory results, as well as serum and plasma samples.
Clinical data were collected prospectively, entered uniformly into a
central database by practitioners at the point of care. All clinical data
arriving at Fresenius undergo rigorous data quality assurance and
quality control auditing. Blood samples collected for clinical care
were shipped to and processed by a central laboratory (Spectra East,
Rockland, NJ). After processing for routine clinical testing, remnant
samples were shipped on ice to the ArMORR Investigators where the
samples were aliquoted and stored in liquid nitrogen. This study was
approved by the Institutional Review Board of the Massachusetts
General Hospital, which waived the requirement for informed
consent, and conducted in accordance with its ethical standards and
the Declaration of Helsinki Principles.
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Study population
Between 1 July 2004 and 30 June 2005, 10,044 incident hemodialysis
patients were prospectively enrolled into ArMORR. We identified
subjects who had 25(OH)D and 1,25(OH)2D levels previously
measured as part of a case–control survival study.19 On the basis of
prior results in a healthy population, we set a minimum sample size
of 80 subjects. To ensure adequate power for racial comparisons, we
randomly selected an approximately equal number of black (n¼ 24)
and white (n¼ 23) patients from the controls, and an equal number
of race-matched cases. Thus, the total sample size was n¼ 94.
Baseline laboratory values were measured from samples collected
within 14 days of dialysis initiation (Figure 3).
Assays
Total 25(OH)D and 1,25(OH)2D were previously measured from
thawed samples in duplicate using a commercially available
radioimmunoassay (DiaSorin, Stillwater, MN). The interassay
coefficients of variation for 25(OH)D were o3% at levels
o30 ng/ml and for 1,25(OH)2D were o6.5% at levels o32.5 pg/ml.
Intact PTH (1–84) was measured using the Nichols Advantage
Biointact-PTH assay by the centralized laboratory.
DBP was measured in duplicate in thawed serum samples by
commercial ELISA (R&D Systems, Minneapolis, MN, catalog
number DVDBP0) according to the manufacturer’s instructions.
The assay was conducted after diluting serum samples to 1 to 2000
in Calibrator Diluent RD6-11 (R&D Systems, part number 895489).
Interassay coefficient of variation was 8.5% at a concentration of
40 mg/ml. The assay recovered between 93 and 110% of a
100–200 mg/ml dose of exogenous DBP added to human serum
samples containing between 25 and 200 mg/ml of endogenous DBP.
There were no differences in the recovery of exogenous DBP in black
patients or obese patients. The manufacturer reports no significant
cross-reactivity with human albumin or vitamin D3.
DBP levels were below the detection limit in five black patients
who died within the first year of dialysis. These individuals were
assigned a DBP value equal to the lowest detectable level (12.3mg/dl).
Calculation of bioavailable vitamin D
Equilibrium dialysis and centrifugal ultrafiltration dialysis have
previously been used by some investigators to indirectly measure
free vitamin D levels, allowing estimation of the binding affinity
constants for 25(OH)D and 1,25(OH)2D with DBP and albu-
min.4,5,32 In these studies, calculated levels of free 25(OH)D and
levels measured by centrifugal ultrafiltration were highly correlated
(r¼ 0.925).5 As previously described, the equations developed by
Vermeulen et al. and originally applied to testosterone were adapted
for determination of bioavailable 25(OH)D and 1,25(OH)2D
levels.6,33 These adapted Vermeulen equations yield free 25(OH)D
levels that are nearly identical to those initially determined by
Bikle et al. while also allowing for identification of bioavailable
(freeþ albumin bound) fractions.5,6 Bioavailable 1,25(OH)2D levels
were determined using the same approach using affinity constants
previously derived by centrifugal ultrafiltration dialysis.4 Details on
the calculation of bioavailable vitamin D levels are presented in
Supplementary Table S1 online.
These affinity constants were previously validated in both healthy
and cirrhotic individuals,4,5 but have not been directly assessed in
hemodialysis patients. We therefore performed a sensitivity analysis
of the main findings using DBP-binding coefficients for 25(OH)D
and 1,252(OH) that were 25% higher or 25% lower than previously
measured values.
Statistical analysis
Before analysis, given the role of albumin as a binding protein for
both vitamin D and calcium, serum calcium levels were corrected
for albumin using the following equation: corrected calcium¼ total
calciumþ 0.8(4–albumin).34 Spearman’s correlation analysis was
performed to assess linear associations. Group comparisons of
vitamin D levels were performed using the Wilcoxon rank sum test.
To examine multivariable associations between bioavailable vitamin
D and PTH, both variables (because of non-normal distribution)
were natural log transformed and analyzed using multivariate linear
regression. All analyses were conducted using the STATA Statistical
Software (STATA, College Station, TX) version 11.
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